[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Erchonia Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637183","a-double-blind-placebo-controlled-evaluation-of-the-effect-of-the-erchonia-evrl-on-chronic-jaw-pain-arising-from-tmj-100637183",false,"NCT07600203","A Double-blind, Placebo-controlled Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ","A Double-blind, Placebo-controlled, Randomized Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ Clinical Study Protocol","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the IRB-approved informed consent form.\n* Adults 22 to 75 years of age.\n* Subject's self-reported rating for jaw pain on the 0-100 VAS pain scale is 50 or greater (≥ 50).\n* Constant jaw pain on-going over at least the past 3 months.\n* Subjects score ≥3 points on the validated TMD Pain Screener (long version).\n* Subject has a primary diagnosis of TMJ-related nociceptive musculoskeletal pain made by a suitably qualified healthcare professional, confirmed using the Diagnostic Criteria for Temporomandibular Disorders (DC\u002FTMD) Axis I, with at least one of the following pain-related diagnoses: myalgia (including local myalgia, myofascial pain, myofascial pain with spreading, myofascial pain with referral) and\u002For arthralgia.\n* Subject is willing and able to refrain from consuming any OTC and\u002For prescription medications including muscle relaxants and\u002For herbal supplements and\u002For recreational and medical drugs including cannabis intended for the relief of pain and\u002For inflammation throughout the course of study participation, except for the study-specific pain relief medication of OTC Tylenol.\n* Subject agrees to refrain from taking a dosage of the study rescue pain medication of over-the-counter Regular Strength Tylenol® tablets for at least 6 hours before a scheduled VAS jaw pain rating is to be recorded. The subject understands that he may take a dosage of the over-the-counter Regular Strength Tylenol® tablets right after the VAS rating has been recorded, if needed to manage jaw pain.\n* Subject is willing and able to refrain from engaging in any non-study procedure therapies for the management of his or her jaw pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture\n* Subject is able to communicate fluently in English with the investigator and is able to read and write English sufficiently to comply with the study procedures.\n\nExclusion Criteria:\n\n* Pain that is undiagnosed or determined by a qualified medical\u002Fdental professional to be primarily attributable to causes other than TMJ-related nociceptive musculoskeletal pain.\n* Diagnosis using the Diagnostic Criteria for Temporomandibular Disorders (DC\u002FTMD) Axis I does not include at least one of the following pain-related diagnoses: myalgia (including local myalgia, myofascial pain, myofascial pain with spreading, myofascial pain with referral) and\u002For arthralgia OR includes one or more of the following pain-related diagnoses: disc displacement disorder with reduction, disc replacement disorder with reduction with intermittent locking, disc displacement disorder without reduction with limited opening, disc displacement disorder without reduction without limited opening, degenerative joint disease, headache attributed to RMD, and subluxation.\n* History of surgical intervention involving the temporomandibular joint within the past 12 months, or any history of total joint replacement or major reconstructive surgery of the TMJ.\n* Intra-articular TMJ interventions, including corticosteroid injections, botulinum toxin injections, or prolotherapy, within 3 months prior to enrollment.\n* Neurologic, neuromuscular, or neuropathic conditions affecting the craniofacial region that could confound TMJ pain assessment, including:\n\n  1. Diagnosed conditions: trigeminal neuralgia, Parkinson's disease, or other neuropathic facial pain disorders\n  2. Pain primarily characterized by neuropathic descriptors (burning, shooting, electric-like, sharp\u002Fstabbing pain, paresthesias, numbness, or tingling).\n* TMJ ankylosis or severe structural deformity requiring surgical intervention.\n* Degenerative disc disease or internal derangement of the temporomandibular joint associated with significant structural degeneration, disc perforation, or requiring surgical intervention.\n* Diagnosed systemic inflammatory or autoimmune conditions that could confound pain assessment (e.g., active rheumatoid arthritis, lupus) unless stable and well controlled.\n* Active cancer or treatment for cancer in the past 6 months.\n* Active infection, wound, or other external trauma to the areas to be treated with the laser.\n* Medical, physical, or other contraindications for, or sensitivity to, light therapy.\n* Pregnant, breast feeding, or planning pregnancy prior to the end of study participation.\n* Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years.\n* Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and\u002For ability to record the necessary study measurements.\n* Any condition or other variable that in the opinion of the investigator may confound or interfere with the evaluation of the effectiveness of the investigational treatment or otherwise render the subject unable to comply with the requirements of the study protocol.","ALL","22 Years","75 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this clinical study is to determine the effectiveness of the Erchonia EVRL, manufactured by Erchonia Corporation (the Company), in providing temporary relief of nociceptive musculoskeletal chronic jaw pain arising from temporomandibular joint (TMJ).",[27,28,29],"TMJ","TMJ Pain","TMD","RECRUITING","2026-05-14",{"date":33,"type":34},"2026-05-20","ACTUAL",{"date":31,"type":34},{"date":37,"type":21},"2027-12-22",{"name":39,"class":40},"Erchonia Corporation","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100566526","an-evaluation-of-the-effect-of-the-erchonia-fx-405-laser-as-an-adjunctive-treatment-of-periodontitis-100566526","NCT06656325","An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis","An Evaluation of the Effect of the Erchonia Corporation FX-405 Laser as an Adjunctive Treatment of Periodontitis","Inclusion Criteria:\n\n* Subject has voluntarily signed a written informed consent form.\n* Male or female 22 to 75 years of age, inclusive.\n* Subject has no evidence of Localized Aggressive Periodontitis.\n* Tooth loss due to periodontitis of ≤ 4 teeth.\n* Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months\n* Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.\n* Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.\n* Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.\n* Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study\n\nExclusion Criteria:\n\n* Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.\n* History of oral cancer or HIV in the last 6 months\n* Pregnant or intending to become pregnant in the next 8 months.\n* Sensitivity to, or contraindication for, light therapy.\n* Currently enrolled in a clinical study of an investigational drug or device.",{"count":50,"type":21},70,[24],"The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.",[54,55,56],"Periodontal Diseases","Periodontitis","Gum Disease",{"date":58,"type":34},"2026-05-18",{"date":60,"type":34},"2025-01-01",{"date":62,"type":21},"2027-08-01",{"name":39,"class":40},2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":41},"100586228","clinical-efficacy-of-the-erchonia-evrl-for-providing-temporary-relief-of-idiopathic-peripheral-neuropathy-foot-pain-100586228","NCT06912646","Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain","An Evaluation of the Effect of the Erchonia® EVRL™ for Prescription Home Use Application in Providing Temporary Relief From Idiopathic Peripheral Neuropathy Foot Pain","Inclusion Criteria:\n\n* Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months.\n* Over the age of 22 years of age\n* Able to read and write English\n* Constant feet pain on-going over at least the past 3 months\n* Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to study enrollment; and be willing and able to not have planned upward dose titration of analgesics during the study period. Decreasing frequency of analgesic use during the study is permitted. Cannabis prescribed for medicinal purposes qualifies as an analgesic in this context\n* Willing and able to refrain from engaging in any non-study therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy, hot or cold packs, and alternative therapies such as chiropractic care and acupuncture\n* Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded\n* Subject's degree of foot pain on the 0-100 VAS, with \"0\" being no pain and \"100\" being worst pain imaginable, is 50 or greater\n\nExclusion Criteria:\n\n* Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher\n* Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism, medications such as chemotherapy, autoimmune disorders, etc..\n* Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during the intended course of study participation\n* Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet\n* Cancerous growths or lesions on or around the treatment area on the feet\n* Difficulty with hand dexterity sufficient to negatively impact the ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.",{"count":73,"type":21},32,[24],"The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.",[77,78],"Neuropathy","Neuropathy;Peripheral","2025-09-05",{"date":81,"type":34},"2025-09-08",{"date":83,"type":34},"2025-05-01",{"date":85,"type":21},"2027-06-16",{"name":39,"class":40},""]